Gyre Therapeutics appoints Rodney Nussbaum to Board and Audit Committee

GYRE THERAPEUTICS, INC.

Rodney Nussbaum appointed Class III director effective March 20, 2024; joins Audit Committee.
Nussbaum is a retired CPA with 40 years at Ernst & Young, KPMG, and Arthur Andersen.
Currently Managing Executive of Atago Advisory, LLC, an accounting advisory firm.
Compensation per non-employee director policy; enters standard indemnification agreement.

item 5.02 item 1.01 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Rodney Nussbaum

Director

GYRE · GYRE THERAPEUTICS, INC.

Effective: 2024-03-20
Filed: March 21, 2024, 7:59 PM ET

appointed Rodney Nussbaum as a Class III director to serve until the Company’s 2024 Annual Meeting of Stockholders and until his successor is duly elected and qualified.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Rodney Nussbaum was appointed as Director at GYRE THERAPEUTICS, INC..

Action: appointed
Role: Director

Exact text from the filing

appointed Rodney Nussbaum as a Class III director to serve until the Company’s 2024 Annual Meeting of Stockholders and until his successor is duly elected and qualified.

View on SEC.gov

GYRE THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001140361-24-014493

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.